Physician profile
David G Dance
NPI 1003064577
$4,147.87
in general payments reported to CMS, 2019-2025
17 companies · $60.05 in 2025
The $60.05 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $32.38 · 2021: $77.95 · 2022: $775 · 2023: $2,843 · 2024: $125 · 2025: $60.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,269 · Food and Beverage: $759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,268.78 |
| Food and Beverage | $759.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $3,065.58 | 2022-2023 | Istent Inject Trabecular Micro-Bypass System, Gsw-Istentinjectwtrabecular Micro-Bypass System, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
| Alcon Vision LLC | $222.49 | 2019-2023 | Clareon |
| Regeneron Healthcare Solutions, INC. | $184.42 | 2019-2023 | Eylea, Eylea Hd |
| Genentech USA, INC. | $148.75 | 2019-2022 | |
| Astellas Pharma US INC | $148.32 | 2023-2024 | Izervay |
| Rxsight INC | $66.05 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Aerie Pharmaceuticals, INC. | $60.67 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $37.80 | 2019-2023 | Lipiflow System Activator (Disposable) |
| Dompe US, INC. | $34.25 | 2025 | Oxervate |
| Ivantis, INC | $27.25 | 2019 | |
| Abbvie INC. | $25.54 | 2022 | |
| Allergan, INC. | $24.27 | 2021 | |
| Alimera Sciences, INC. | $23.83 | 2023 | Yutiq |
| Mallinckrodt Enterprises LLC | $23.04 | 2019 | |
| Merz Pharmaceuticals, LLC | $21.57 | 2023 | Xeomin |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $19.40 | 2022 | |
| Sun Pharmaceutical Industries INC. | $14.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.